Membrane fusion is the primary step
in the entry of enveloped viruses
into the host cell. Membrane composition modulates the membrane fusion
by changing the organization dynamics of the fusion proteins, peptides,
and membranes. The asymmetric lipid compositions of the viral envelope
and the host cell influence the membrane fusion. Cholesterol is an
important constituent of mammalian cells and plays a vital role in
the entry of several viruses. In our pursuit of developing peptide-based
general fusion inhibitors, we have previously shown that a coronin
1-derived peptide, TG-23, inhibited polyethylene glycol-induced fusion
between symmetric membranes without cholesterol. In this work, we
have studied the effect of TG-23 on the polyethylene glycol-mediated
fusion between 1,2-dioleoyl-sn-glycero-3-phosphocholine
(DOPC), 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine
(DOPE), and 1,2-dioleoyl-sn-glycero-3-phospho-(1′-rac-glycerol)
(DOPG) (60/30/10 mol %) and DOPC/DOPE/DOPG/CH (50/30/10/10 mol %)
membranes and between DOPC/DOPE/DOPG (60/30/10 mol %) and DOPC/DOPE/DOPG/CH
(40/30/10/20 mol %) membranes. Our results demonstrate that the TG-23
peptide inhibited the fusion between membranes containing 0 and 10
mol % cholesterol though the efficacy is less than that of symmetric
fusion between membranes devoid of cholesterol, and the inhibitory
efficacy becomes negligible in the fusion between membranes containing
0 and 20 mol % cholesterol. Several steady-state and time-resolved
fluorescence spectroscopic techniques have been successfully utilized
to evaluate the organization, dynamics, and membrane penetration of
the TG-23 peptide. Taken together, our results demonstrate that the
reduction of the inhibitory effect of TG-23 in asymmetric membrane
fusion containing cholesterol of varying concentrations is not due
to the altered peptide structure, organization, and dynamics, rather
owing to the intrinsic negative curvature-inducing property of cholesterol.
Therefore, the membrane composition is an added complexity in the
journey of developing peptide-based membrane fusion inhibitors.